PROKIDNEY CORP. (PROK)
D
Pipeline Grade
Financial Position (from SEC Filings)
$101.9M
Cash & Equivalents
$41.7M
Quarterly Burn Rate
7 mo
Est. Cash Runway
$532M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05918523 | A Long-Term Follow-Up Study of Participants Exposed to REACT | OTHER | Recruiting | 80 |
| NCT06790498 | Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product | OTHER | Enrolling By Invitation | 50 |
| NCT05099770 | Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease | PHASE3 | Recruiting | 685 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.